[{"data":1,"prerenderedAt":205},["ShallowReactive",2],{"drug-deflazacort":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":67,"contraindications":98,"warnings":108,"renal":118,"monitoring":119,"interactions":120,"review":121,"examples":124,"atc":132,"iran":134,"usApproval":150,"links":156,"populations":172},"deflazacort",1,{"fa":7,"en":8},"دفلازاکورت","Deflazacort","systemic-hormones",{"fa":11,"en":12},"کورتیکواستروئید","Corticosteroid",[14],{"name":15,"market":16},"Emflaza","US",[18,7],"emflaza",[20,33,43,51,59],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":28,"refs":29},"susp","suspension","oral","22.75 mg\u002FmL oral suspension",{"amount":26,"unit":27,"perVolumeMl":5},22.75,"mg",[16],[30],{"source":31,"section":32},"fda-emflaza","3",{"id":34,"form":35,"route":23,"label":36,"concentration":37,"markets":40,"refs":41},"tab-6","tablet","6 mg tablet",{"amount":38,"unit":27,"perUnit":35,"scored":39},6,false,[16],[42],{"source":31,"section":32},{"id":44,"form":35,"route":23,"label":45,"concentration":46,"markets":48,"refs":49},"tab-18","18 mg tablet",{"amount":47,"unit":27,"perUnit":35,"scored":39},18,[16],[50],{"source":31,"section":32},{"id":52,"form":35,"route":23,"label":53,"concentration":54,"markets":56,"refs":57},"tab-30","30 mg tablet",{"amount":55,"unit":27,"perUnit":35,"scored":39},30,[16],[58],{"source":31,"section":32},{"id":60,"form":35,"route":23,"label":61,"concentration":62,"markets":64,"refs":65},"tab-36","36 mg tablet",{"amount":63,"unit":27,"perUnit":35,"scored":39},36,[16],[66],{"source":31,"section":32},[68],{"id":69,"disease":70,"label":71,"population":74,"type":78,"unit":27,"dose":79,"refs":81,"allowedFormulations":84,"notes":85},"dmd","duchenne",{"fa":72,"en":73},"دیستروفی دوشن (۲ سال به بالا) — حدود ۰٫۹ mg\u002Fkg یک بار در روز","Duchenne muscular dystrophy (≥2 y) — about 0.9 mg\u002Fkg once daily",{"minAge":75},{"value":76,"unit":77},2,"year","weightBased",{"perKgPerDay":80,"dividedDoses":5},0.9,[82],{"source":31,"section":83},"2.2",[21],[86],{"text":87,"refs":90},{"fa":88,"en":89},"قرص: به نزدیک‌ترین دوز ممکن (ترکیب ۴ قدرت) گرد به بالا؛ سوسپانسیون: به نزدیک‌ترین ۰٫۱ mL بالا. مصرف بیش از چند روز: قطع تدریجی. با مهارکننده متوسط\u002Fقوی CYP3A4 یک‌سوم دوز. واکسن زنده ۴ تا ۶ هفته قبل.","Tablets: round up to the nearest possible dose (any combination of the 4 strengths); suspension: round up to the nearest 0.1 mL. After more than a few days: taper. Moderate\u002Fstrong CYP3A4 inhibitors: one-third of the dose. Live vaccines 4–6 weeks before starting.",[91,92,94,96],{"source":31,"section":83},{"source":31,"section":93},"2.3",{"source":31,"section":95},"2.5",{"source":31,"section":97},"2.1",[99],{"id":100,"severity":101,"text":102,"refs":105},"hyper","block",{"fa":103,"en":104},"حساسیت به دفلازاکورت یا اجزای فرآورده.","Hypersensitivity to deflazacort or its inactive ingredients.",[106],{"source":31,"section":107},"4",[109],{"text":110,"refs":113},{"fa":111,"en":112},"سرکوب محور HPA، کوشینگ، هیپرگلیسمی؛ عفونت؛ افزایش فشار و کاهش پتاسیم؛ سوراخ شدن گوارش. سوسپانسیون بنزیل الکل دارد (زیر ۲ سال نه).","HPA-axis suppression, Cushing’s, hyperglycaemia; infections; raised BP and low potassium; GI perforation. Suspension contains benzyl alcohol (not under 2 y).",[114,116],{"source":31,"section":115},"5",{"source":31,"section":117},"8.4",[],[],[],{"status":122,"reviewer":123,"date":123},"unverified",null,[125],{"regimen":69,"formulation":21,"input":126,"expect":129},{"ageYears":127,"weightKg":128},8,25,{"perDose":130,"mlPerDose":131},22.5,0.99,[133],"H02AB13",{"status":135,"forms":136,"refs":145},"registered",[137,141],{"code":138,"en":139,"fa":140},"12318","DEFLAZACORT 5MG TAB","قرص دفلازاکورت ۵ میلی‌گرم",{"code":142,"en":143,"fa":144},"06078","DEFLAZACORT 6MG TAB","قرص دفلازاکورت ۶ میلی‌گرم",[146],{"source":147,"section":148,"url":149},"darooyab-generic","G-2086\u002FDeflazacort","https:\u002F\u002Fwww.darooyab.ir\u002FG-2086\u002FDeflazacort",{"kind":151,"refs":152,"id":155},"NDA",[153],{"source":31,"section":154},"SPL approval \u002F marketing category","NDA208684",[157,160,164,167,170],{"kind":158,"url":159,"label":155},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=208684",{"kind":161,"url":162,"label":163},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=31b347d2-f156-4055-9d8f-7cf0df420296","FDA Emflaza",{"kind":165,"url":166,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa617024.html",{"kind":168,"url":169,"label":133},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=H02AB13",{"kind":171,"url":149,"label":8},"darooyab",{"pregnancy":173,"lactation":182,"pediatric":190,"geriatric":197},{"level":174,"text":175,"quote":178,"refs":179},"caution",{"fa":176,"en":177},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",[180],{"source":31,"section":181},"8.1",{"level":174,"text":183,"quote":186,"refs":187},{"fa":184,"en":185},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.",[188],{"source":31,"section":189},"8.2",{"level":174,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of EMFLAZA for the treatment of DMD have been established in patients 2 years of age and older.",[196],{"source":31,"section":117},{"level":174,"text":198,"quote":201,"refs":202},{"fa":199,"en":200},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with EMFLAZA.",[203],{"source":31,"section":204},"8.5",1792156173034]